Stock recommendations are expert suggestions designed to guide investors in making informed decisions about buying, selling, or holding stocks. These recommendations are typically based on thorough market analysis, company performance, and other relevant factors.
A buy recommendation indicates that a stock is expected to increase in value, making it a good investment. This is usually due to positive market trends, strong company fundamentals, or other favorable conditions that suggest the stock will rise in price.
Here are a few stocks recommended by analysts with a high growth potential of up to 35 percent
1. Avenue Supermarts Ltd
Avenue Supermarts operates the DMart retail chain, known for offering a wide range of products like groceries, FMCG, and household items at competitive prices. It was founded by Radhakishan Damani and has grown rapidly due to its efficient cost model and strong supply chain. The company focuses on value retailing and targets middle-income households.
CLSA, a prominent Global brokerage firm, has recommended a “Buy” call on Avenue Supermarts Ltd with a target price of Rs. 6,406 per share, indicating an upside potential of 35 percent from today’s close price of Rs. 4750.00.
Rationale
The rationale behind CLSA’s ₹6,406 target for Avenue Supermarts is based on DMart’s strong competitive advantages, including consistently lower prices, a wide product assortment, and deep customer loyalty. Additionally, CLSA believes current valuations do not fully reflect the company’s accelerated store expansion, rising private-label penetration, and a strengthening profitability moat.
2. Cohance Lifesciences Ltd
Cohance Lifesciences is a relatively newer name in the Indian pharmaceutical and life sciences sector. It typically focuses on active pharmaceutical ingredients (APIs), contract development, and manufacturing services (CDMO). The company aims to provide integrated solutions to global pharma companies. Its operations span research, manufacturing, and regulatory support.
Jefferies, a prominent Global brokerage firm, has recommended a “Buy” call on Cohance Lifesciences Ltd with a target price of Rs. 1,150 per share, indicating an upside potential of 27 percent from today’s close price of Rs. 904.00.
Rationale
The rationale for Jefferies’ ₹1,150 target on Cohance Lifesciences is based on the company’s strong positioning to benefit from growth in the Antibody Drug Conjugates (ADC) industry. Cohance’s integrated ADC platform, new customer acquisitions, diversification into specialty chemicals, and robust pipeline. Additionally, as big pharma companies increasingly diversify to India, Cohance stands to capture significant growth opportunities across multiple segments, which is not yet fully priced into the stock.
3. Kotak Mahindra Bank Ltd
Kotak Mahindra Bank is one of India’s leading private sector banks, offering a wide range of financial services including retail and corporate banking, asset management, insurance, and investment banking. Started by Uday Kotak, it evolved from a finance company to a full-fledged bank in 2003. The bank is known for its conservative risk profile and strong financial performance.
UBS, a prominent Global brokerage firm, has recommended a “Buy” call on Kotak Mahindra Bank Ltd with a target price of Rs. 2,450 per share, indicating an upside potential of 25 percent from today’s close price of Rs. 1967.65.
Rationale
The rationale behind UBS’s upgrade of Kotak Mahindra Bank to Buy with a ₹2,450 target is based on the bank’s diversified growth drivers. UBS emphasized Kotak’s strong non-lending businesses, including asset management and insurance, which offer greater stability and resilience compared to peers.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
